Bold claim: GLP-1 drugs are not just blood-sugar savers—they’re reshaping obesity, diabetes, and heart health all at once. But here’s where it gets controversial: the latest Lancet review suggests these medicines may offer far more than temporary weight loss, potentially protecting the heart, kidneys, and liver while transforming how we treat metabolic disease.
A comprehensive synthesis in The Lancet gathers decades of research on incretin-based therapies. It centers on GLP-1 receptor agonists, newer multi-receptor combinations, and emerging oral options. The authors confirm that synthetic GLP-1 medications such as semaglutide and tirzepatide, initially developed for glucose control, provide proven cardiovascular and renal protection and improvements in liver-related outcomes tied to metabolic disease. They also spotlight exciting “next-generation” approaches that, in clinical trials, achieve weight losses up to around 24%—nearly on par with some surgical interventions.
Background
Historically, type 2 diabetes (T2D) and obesity were treated as separate battles. Diabetes relied on insulin or metformin to control blood sugar, while obesity often depended on lifestyle changes or less effective drugs. Incretin-based therapies—synthetic medicines that mimic gut hormones to boost insulin production and curb appetite—revolutionized the field. GLP-1 receptor agonists like semaglutide and tirzepatide have shown clear benefits for both conditions, triggering metabolic pathways that improve overall outcomes.
Yet clinical research has increasingly shown that metabolic disease often comes with a cluster of systemic problems—heart failure, chronic kidney disease, and fatty liver disease—that single-target drugs seldom address. New generations of incretin-based therapies aim to tackle multiple pathways at once, seeking to improve metabolic control and downstream organ health.
About the review
This Review assembles evidence from major randomized trials and development programs, drawing on literature identified through PubMed and focusing on advances through October 2025. It covers several classes of therapies:
- Mono-agonists: liraglutide, dulaglutide, and semaglutide
- Dual agonists: tirzepatide (GLP-1/GIP) and survodutide (glucagon/GLP-1)
- Triple agonists: retatrutide (GIP/GLP-1/glucagon)
- Oral small molecules: orforglipron
The authors evaluate these drugs across diverse groups: people with established T2D, obesity, cardiovascular disease, and chronic kidney disease. Rather than performing a new meta-analysis, they synthesize findings from major trials, focusing on metrics like HbA1c, percent weight loss, major adverse cardiovascular events (MACE), and kidney function decline reported in large CVOTs, obesity trials, and early-phase studies. Safety and tolerability are also examined, with emphasis on gastrointestinal side effects and concerns about lean mass loss during substantial weight reduction.
Key findings
- Incretin-based therapies have achieved diabetes and obesity control while delivering meaningful benefits to heart, kidney, and liver health. CVOTs show consistent cardiovascular advantages; for example, in obesity without diabetes, semaglutide reduced MACE risk by about 20% in the SELECT trial. Some secondary outcomes didn’t reach statistical significance due to the trial’s testing framework, but the overall signal is favorable.
- Kidney protection is evident: in the FLOW trial, semaglutide lowered the risk of severe kidney outcomes (including kidney failure and death) by roughly 24%.
- Newer agents may offer greater weight loss. Tirzepatide outperformed semaglutide in head-to-head trials, with about 20% vs. 14% weight loss. In early studies, retatrutide achieved weight reductions up to ~24% over 48 weeks.
- Oral options like orforglipron provide non-injectable weight loss, with results up to ~11% over 72 weeks, appealing to patients seeking needle-free therapy.
- These drugs also address comorbidities: tirzepatide has reduced apnea-hypopnea index in obstructive sleep apnea, and both semaglutide and tirzepatide show promise for MASLD, with improvements in liver fat and fibrosis-related endpoints.
- Individual responses vary and weight regain can occur if treatment stops, underscoring obesity’s chronic nature and the need for ongoing therapy.
Clinical implications and considerations
The review underscores how synthetic incretin-based medications extend beyond glycemic control to meaningful organ protection and multi-system benefits. The emergence of triple agonists and oral formulations promises to lower barriers to treatment and enhance outcomes. However, clinicians should balance efficacy with tolerability, as gastrointestinal side effects remain a challenge, and dose-escalation strategies are often necessary. Moreover, maintaining lean mass during significant weight loss should be a priority, suggesting a role for exercise and nutrition strategies alongside pharmacotherapy.
Bottom line
Incretin-based therapies have shifted the paradigm in metabolic disease care. They deliver robust weight loss and glycemic control while offering protection for the heart, kidneys, and liver. Ongoing developments—especially triple agonists and oral options—could broaden access and improve results further. Yet the need to preserve muscle during weight loss and manage gastrointestinal side effects means patient-specific treatment plans and monitoring remain crucial.
Source: Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026). Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet, 407(10531), 892–908. DOI: 10.1016/S0140-6736(25)02105-1.
